Thyroid hormone (TH) impact on the proliferation of on human melanoma (me) cells and treatment with the synthetic rexinoid bexarotene

PROCOPIO CAROLINA; MERCEDES DEBERNARDI; ROSEMBLIT, CINTHIA; CREMASCHI GRACIELA; CAYROL FLORENCIA

Congreso; LXV Reunión anual SAIC; 2020

With a constantly increasing worldwide incidence, melanoma (ME) represents the most lethal tumor among all skin cancers. Despite novel target therapies and immunotherapies improve overall survival rates, only a part of ME patients benefits from this therapies and others develops drug resistance, making crucial the study of new compounds for ME treatment.Bexarotene (Bex), an RXR agonist used for cutaneous T cell lymphoma treatment, is currently being studied as alternative therapy for other types of cancer. The first aim of this work was to evaluate Bex effect on A375 and WM35 human melanoma cell lines in vitro. We found that Bex significantly decreases cell viability after 48h of both ME cell lines in a dose dependent manner (p